key: cord-0071207-lvor8ods
authors: Fattizzo, Bruno; Pasquale, Raffaella; Bellani, Valentina; Barcellini, Wilma; Kulasekararaj, Austin G.
title: Complement Mediated Hemolytic Anemias in the COVID-19 Era: Case Series and Review of the Literature
date: 2021-11-25
journal: Front Immunol
DOI: 10.3389/fimmu.2021.791429
sha: c40e3a18cb6f79a1540a05dadc00a064233b147d
doc_id: 71207
cord_uid: lvor8ods

The complex pathophysiologic interplay between SARS-CoV-2 infection and complement activation is the subject of active investigation. It is clinically mirrored by the occurrence of exacerbations of complement mediated diseases during COVID-19 infection. These include complement-mediated hemolytic anemias such as paroxysmal nocturnal hemoglobinuria (PNH), autoimmune hemolytic anemia (AIHA), particularly cold agglutinin disease (CAD), and hemolytic uremic syndrome (HUS). All these conditions may benefit from complement inhibitors that are also under study for COVID-19 disease. Hemolytic exacerbations in these conditions may occur upon several triggers including infections and vaccines and may require transfusions, treatment with complement inhibitors and/or immunosuppressors (i.e., steroids and rituximab for AIHA), and result in thrombotic complications. In this manuscript we describe four patients (2 with PNH and 2 with CAD) who experienced hemolytic flares after either COVID-19 infection or SARS-Cov2 vaccine and provide a review of the most recent literature. We report that most episodes occurred within the first 10 days after COVID-19 infection/vaccination and suggest laboratory monitoring (Hb and LDH levels) in that period. Moreover, in our experience and in the literature, hemolytic exacerbations occurring during COVID-19 infection were more severe, required greater therapeutic intervention, and carried more complications including fatalities, as compared to those developing after SARS-CoV-2 vaccine, suggesting the importance of vaccinating this patient population. Patient education remains pivotal to promptly recognize signs/symptoms of hemolytic flares and to refer to medical attention. Treatment choice should be based on the severity of the hemolytic exacerbation as well as of that of COVID-19 infection. Therapies include transfusions, complement inhibitor initiation/additional dose in the case of PNH, steroids/rituximab in patients with CAD and warm type AIHA, plasma exchange, hemodialysis and complement inhibitor in the case of atypical HUS. Finally, anti-thrombotic prophylaxis should be always considered in these settings, provided safe platelet counts.

There is an increasing interest in the relationship between COVID-19 infection and complement activation. Several reports highlighted that the virus is able to induce an over inflammatory state encompassing the activation of various pathways such as coagulation (namely thrombo-inflammation) and the complement cascade (1) (2) (3) . The latter is a complex system which may be activated by three different ways: the classical, the lectin and the alternative pathway. The former two require the presence of a specific trigger, either an immune-complex or an infectious agent. The complement alternative pathway is homeostatically active and its functioning may be amplified in the presence of triggers. Complement-mediated hematologic diseases include paroxysmal nocturnal hemoglobinuria (PNH), autoimmune hemolytic anemia (AIHA), particularly cold agglutinin disease (CAD), and hemolytic uremic syndrome (HUS). PNH is caused by the acquisition of somatic mutation of PIG-A gene resulting in the loss of glycosylphosphatidylinositolanchored proteins, including the complement inhibitors CD55 and CD59. PNH cells are therefore subject to complementmediated destruction that mainly involves erythrocytes with consequent hemolytic anemia. PNH is managed successfully with terminal complement inhibitors targeting C5 (eculizumab or ravulizumab) with good control of intravascular hemolysis (IVH), but potentially inducing iatrogenic extravascular hemolysis (EVH) which is targeted by novel C3 inhibitors (4) . CAD is an autoimmune hemolytic anemia caused by cold reactive antierythrocyte autoantibodies usually of the IgM class that are intrinsically able to fix complement with consequent positivity of the direct antiglobulin test (DAT) for C3d (5) . This may result in both IVH and EVH due to either terminal activation of complement and membrane attack complex (MAC) formation, or C3b deposition on erythrocytes and reticulo-endothelial phagocytosis. CAD is mainly treated with immunosuppressants (steroids and the anti-CD20 monoclonal antibody rituximab) and complement inhibitors are in clinical trials with promising results (6) . Complement activation may be observed even in warm type AIHA (wAIHA), particularly in case of high levels of IgG antierythrocyte autoantibodies, resulting in DAT positivity for IgG+C. IgG+C wAIHAs are generally more severe and show higher relapse frequency. Clinical trials with complement inhibitors in wAIHA are also ongoing (7) . HUS is a thrombotic microangiopathy characterized by the formation of platelet microthrombi in arterioles and capillaries, causing platelet consumption, nonimmune hemolytic anemia, and acute renal injury. Typical HUS is caused by Shiga-like toxin (verotoxin) produced by Escherichia coli (O157: H7) and Shiga toxin by Shigella dysenteriae. The atypical form may be secondary to bacteria, medication, or immune processes capable of endothelial damage, or to congenital or acquired conditions inducing widespread complement activation, such as atypical familial HUS. In the latter cases C5 inhibitors are employed with clinical benefit (8) . All these complement-mediated hemolytic conditions may experience exacerbations upon several triggers including infections, surgery, traumas (4, 5) . Particularly, hemolytic flares in PNH patients on complement inhibitors are denominated breakthrough hemolysis (BTH) (4). COVID19 infection and its vaccine are also possible triggers through various mechanisms including lectin-and alternative pathway activation by Nucleocapside and Spike viral proteins, molecular mimicry and autoantibody production with activation of the classical pathway, etc (1) . In this manuscript we describe four patients who experienced PNH BTH and CAD exacerbation after either COVID infection or SARS-Cov2 vaccine and we review the most recent literature.

We report four patients, 2 with PNH and 2 with CAD, diagnosed according to the current guidelines (4, 5) and regularly followed at a tertiary university hospital in Milan, Italy, who experienced hemolytic flares during COVID-19 infection or after SARS-CoV-2 vaccine.

The study was conducted according the Declaration of Helsinki and approved by the local Ethical Committee. Patients signed informed consent.

We conducted a review of the literature about complement mediated hemolytic anemias and COVID-19 infection and SARS-CoV-2 vaccine by searching for indexed articles and published abstracts until September 2021 in MEDLINE via PubMed and the National Library of Medicine. The following keywords were used: paroxysmal nocturnal hemoglobinuria; cold agglutinin disease; SARS-CoV-2; COVID19 vaccine; hemolytic uremic syndrome; autoimmune hemolytic anemia; and complement. We selected only studies including human subjects with a clear diagnosis of PNH, CAD, AIHA, HUS, and reporting data on treatment and outcome of COVID-19 infection and of the hemolytic flare.

A 27-year-old man was diagnosed with PNH in 2010 (granulocyte clone size 93%) associated with transfusion dependent anemia (Hb 6.8 g/dL, LDH 7.5 x upper limit of normality, ULN, PLT 121x10 9 /L, neutrophils 1.8 x10 9 /L, reticulocytes 121x10 9 /L) and symptoms of hemolysis with abdominal pain. He was immediately started on eculizumab 900 mg fortnightly with good response (Hb 11.1 g/dL, LDH 1.1xULN, reticulocytes 51x10 9 /L). In March 2021, a nasopharyngeal swab for SARS-Cov-2 performed for screening purposes was positive and the patient was initially asymptomatic. Two days later, he presented to the emergency room complaining of shortness of breath, asthenia, and dark urine. Hb was 6.1 g/dL and LDH increased to 10.7 x ULN. A CT scan revealed bilateral interstitial pneumonia and he was admitted to hospital and treated with antibiotics, dexamethasone, and low molecular weight heparin (LMWH), as well as an earlier dose of eculizumab (10 days after the previous one). During admission he also required red blood cells (RBC) transfusion (3 units) and progressively recovered. (9) (10) (11) (12) (13) (14) (15) (16) . Patients were mostly women (63% females, 37% males), with a wide age range (19 to 77 years). 15 patients were on active therapy with a complement inhibitor, and four were treatment naïve. The great majority (89.4%) experienced a mild to moderate COVID-19 infection, whilst only two subjects needed intensive care unit admission and one died of respiratory failure (11, 14) . PNH flares had heterogenous severity with some patients requiring RBC transfusions and additional doses of complement inhibitors, and other experiencing only mild Hb reduction with slight LDH elevation. Importantly, no thrombotic episodes were reported. Specifically, Pike et al. reported the experience of the Leeds Paroxysmal Nocturnal Hemoglobinuria national service. Within their PNH cohort, they observed COVID-19 infection in 4 patients on anti-complement therapy (3 eculizumab, 1 ravulizumab); 75% experienced a BTH and one patient died from respiratory failure after being intubated, despite additional doses of eculizumab for ongoing haemolysis (14) . Similarly, Barcellini et al. analyzed the experience of eight Italian PNH reference centers and reported 4 patients who had positive SARS-Cov-2 on routine surveillance SARS-Cov-2 nasalpharyngeal swab. Only two subjects developed mild respiratory symptoms and only one experienced BTH. None of them required hospitalization (16) . Additionally, Kulasekararaj et al. reported the clinical course, degree of intravascular hemolysis and outcomes of COVID-19 in four PNH patients, and showed a beneficial effect of complement inhibition both in controlling the intravascular haemolysis and in dampening the hyperinflammatory lung damage due to COVID-19 (13) .

Our case report along with the review of the literature suggest that PNH hemolytic flares may occur during COVID-19 infection and may be handled with transfusion support and additional doses of complement inhibitors. The latter, rather than increasing the risk of a more severe COVID-19 infection, appear to dampen the over-inflammatory state induced by SARS-CoV-2 (16, 17) . Additionally, the role of complement activation in both early (18) and late stage (19) COVID-19 infection and the potential to target them with ravulizumab is currently being studied in two randomized controlled trials. The latter trial was interrupted early due to futility on interim analysis. The fact that no thrombotic events were observed during these acute hemolytic episodes suggest a further protective role of complement inhibition and may also be in keeping with the high level of medical surveillance/patient education in PNH patients.

A 17-year-old man was diagnosed with classic hemolytic PNH in a low-income Country in 2019 and was managed with vitamin and iron support, warfarin prophylaxis, and RBC transfusions during hemolytic crises. In March 2021, he came to our center and was started on eculizumab with optimal control of intravascular hemolysis and warfarin was stopped. In July 2021, 5 days after the first dose of Pfizer mRNA vaccine (14 days after prior eculizumab dose), he experienced a decrease of 1.5 g/dL Hb (from 12.6 to 11.1 g/dL) associated with an increase in unconjugated bilirubin (1.9 to 3.2 mg/dL) and LDH levels (from normal to 2 x ULN). He complained of mild abdominal pain and urine darkening in the last 2 days. He received eculizumab treatment and symptoms progressively recovered soon after therapy. One-week later laboratory parameters were normalized.

mRNA-based vaccines act by inducing the expression of SARS-Cov-2 Spike protein in order to elicit immune recognition and antibody response. Yu Four, all on intravenous ravulizumab and one in combination therapy with D inhibitor danicopan, showed signs of BTH from the vaccine day up to 5 days later, 2 with severe anemia, and 1 requiring transfusion support. Interestingly, only 1 patient who was therapy naïve experienced a likely thrombotic episode. Five days after the second dose of the Pfizer-BioNTech vaccine, he developed abdominal pain and CT scan showed peripancreatic fat stranding indicating possible small bowel microvascular thrombosis; D-dimer was elevated, and the patient was initiated on ravulizumab with signs and symptoms recovery (21) . We previously described another case of PNH on treatment with subcutaneous ravulizumab displaying severe BTH the day after the second dose of Moderna vaccine. She was handled with supportive treatment and recombinant erythropoietin with progressive recovery. The latter, along with that reported in the present report, were the only 2 BTH episodes observed after SARS-CoV-2 vaccine in our cohort of 13 PNH patients on active complement inhibition who received mRNA SARS-CoV-2 vaccine from March 2021 at our center (23) .

These experiences indicate that hemolytic exacerbations may occur in PNH patients after SARS-Cov-2 vaccine so that monitoring of blood counts and hemolytic markers in the week after vaccine doses is advisable. Patient education to recognize signs/symptoms of PNH activity is pivotal, particularly in naïve patients who may be at higher risk of developing thrombotic complications. Although Gerber et al. observed BTH episodes in patients receiving COVID-19 vaccine more than 4 weeks after last ravulizumab dose, hemolytic flares may occur as soon as the day after the last complement inhibitor administration, so that it is difficult to suggest a specific timing, although it would be advisable to give vaccinations closer to anti-complement therapy (21) . Importantly, transfusion requirement was rarer after COVID-19 vaccine than during infection, and no fatalities were reported in PNH after vaccination, confirming that vaccine expected benefits still outweigh the risks. Additionally, the risk of complement activation after Neisseria meningitis vaccination, and leading to thrombosis in patients with PNH has been reported (24) .

A 68-year-old female diagnosed with CAD in 2017 previously treated with steroids and rituximab with response, was admitted to hospital in April 2020 due to fever and shortness of breath. She complained of dark urine and jaundice during the previous 5 days. Swab and CT scan revealed SARS-CoV-2 pneumonia and laboratory tests showed severe anemia (Hb 5.1 g/dL) with increased LDH 2.1 xULN. Direct antiglobulin test was confirmed positive for complement at high titer and consumption of C3 and C4 was noted (C3 <77 mg/dL, C4 undetectable). The patient was managed with oxygen support, hydroxychloroquine, antibiotics, steroids, and LMWH for COVID-19. For CAD reactivation, the patient received a total of 6 RBC transfusions during a period of 27 days. The clinical picture progressively improved and hemolytic anemia recovered, thereby allowing steroid tapering (from 50 mg day of prednisone reduced by 10 mg week until 25 mg day, then by 5 mg week until stop in about 8 weeks).

Available literature regarding CAD development or reactivation during COVID-19 infection is summarized in Table 3 (25-42) . From March 2020, we found 20 reports of patients experiencing cold agglutinin mediated hemolysis after COVID-19 infection (11 males, 9 females, aged from 17 to 77 years). Only 2 patients had a previous history of CAD (30, 42) whilst the others were firstly diagnosed after SARS-CoV-2 infection. All but 2 patients experienced mild to severe respiratory involvement, thereby requiring steroids, hydroxychloroquine, antibiotics, antiviral, tocilizumab, and intubation. Concerning CAD treatment, 12 patients received RBC transfusions, 8 high dose steroids, and 3 rituximab. Two patients received plasma exchange, one for CAD and one for COVID-19 itself. Four patients died despite medical interventions. One fatality occurred in a patient who experienced severe COVID-19 disease with deep venous thrombosis of upper extremities and cerebrovascular disease (33) . Given the known risk of thrombosis in patients with CAD, the authors speculated that this may have contributed to thrombosis and to the unfavorable outcome. Accordingly, other investigators have suggested that the development of autoimmune hemolysis may represent a risk factor for worse outcome in COVID-19 patients. Specifically, Algassim et al. reported that 14.7% of intensive care unit (ICU) patients with COVID-19, and 9% of non-ICU patients, had AIHA (46) . These patients had significantly more severe courses with longer hospital stay as compared with anemic patients without AIHA. Although anemia and increased levels of LDH and other hemolytic markers may be nonspecifically observed during severe infections, autoimmune hemolysis should be suspected in the context of an unexplained or persistent anemia in patients with COVID-19. From a pathogenic point of view, molecular mimicry among SARS-CoV-2 antigens and red cells seem the prominent mechanism, as also described for CAD developing after Mycoplasma infection (47) . Additionally, the hyperinflammation triggered by the virus itself may result in cross activation of the immune system against self-antigens in an "innocent bystander" fashion. This includes the complement cascade that may be activated through both the classic and lectin pathway. Furthermore, the oxidative stress against erythrocyte and platelet membranes typical of the septic state, may favor the exposure of phosphatidyl serine (PS) and consequent complement deposition, thus causing blood cell consumption (47) (48) (49) .

Overall, the association between CAD development/ reactivation and COVID-19 infection has been reported with more than half cases showing severe anemia requiring transfusions. Interestingly, the proportion of COVID-19associated CAD is greater than what generally observed with CAD among all AIHAs, where CAD represent about 20% of cases (5) . Most cases resolved with steroids and along with resolution of COVID-19 infection, but thrombotic episodes may occur and require prophylaxis (as also suggested for COVID-19 infection itself). Finally, it is still debated whether rituximab can be safely administered during septic state, and in most cases this treatment was deferred to allow recovery of active infection (50) .

A 59-year-old male suffering from CAD since 2019, and previously treated with rituximab, had an Hb drop from 10.1 to 6.8 g/dL and LDH elevation (1.8 xULN) 5 days after the second dose of Moderna vaccine. The levels of complement fractions were also decreased, with C3 55 mg/dL (normal values >77 mg/dL) and undetectable C4. He had also experienced fever and pain at the injection site and complained of dark urine and jaundice starting the day after vaccination. He received steroids (1 mg/Kg day prednisone) and recombinant erythropoietin (40,000 UI/week of epoetin alpha subcutaneously) and Hb stabilized at about 8.2 g/dL. Two weeks later, rituximab was administered with progressive and complete recovery, allowing steroid tapering.

As shown in Table 4 , only 4 cases of CAD or mixed form of AIHA (i.e., direct anti-globulin test positive for IgG plus C at high titer) developing (N=2) or reactivating (N=2) after SARS-CoV-2 vaccination have been reported (23, 28, 51, 52) . Al Aoun et al. reported a 45-year-old female patient developing severe CAD 3 days after the first dose of Pfizer vaccine. The patient was treated with blood transfusion and rituximab, achieving complete remission 8 weeks later (51). Brito et al. reported an 88-year-old woman who developed very severe AIHA (Hb 4.5 g/ dL) complicated by acute kidney injury two days after the second dose of an mRNA vaccine (not specified). The DAT revealed very high titers of anti-erythrocyte IgG autoantibodies and high anti-C3d titers. The patient was treated with methylprednisolone 1 g boluses and was transfused with subsequent Hb stabilization and amelioration of hemolytic markers (52) . As regards exacerbations of pre-existing CAD, Lamas et al. reported a 57year-old female who experienced shortness of breath, jaundice and mild hemoglobinuria 2 days after the first dose of an mRNA vaccine (not specified); hb had decreased to 8.6 g/dL and the patient received prednisone 20 mg daily with progressive improvement. The same episode occurred 2 days after the second dose of the same vaccine. Anti-Spike IgG testing showed that the patient had efficiently seroconverted (55) . Interestingly, our group reported the results of a prospective monitoring of 58 individuals with AIHA, including 15 CAD during SARS-CoV-2 vaccination campaign. This consisted in testing Hb and LDH levels the week before and after each vaccine dose. We detected 3 warm AIHA and 1 CAD reactivation, all effectively managed with steroids and/or rituximab (23).

The case described and data from literature show that SARS-CoV-2 vaccination may be associated with CAD development as well as with exacerbation in less than 10% of pre-existing CAD cases (i.e., 1/15 in our experience). CAD exacerbations are unpredictable, may occur after either after the first or the second dose, and regardless of vaccine type. Since most cases may be successfully managed with steroids and transfusion, prospective hematologic monitoring as adopted in our survey (1 week before, 1 week after the first and the second dose) appears appropriate to intercept and manage hemolytic flares.

Similarly to what described for PNH, CAD episodes following COVID-19 vaccine are milder than those following infection, with no thrombotic nor fatal events, strengthening the message that the benefits of vaccination greatly outweigh the risks.

Eleven patients with warm type AIHA developing or reactivating during COVID-19 infection have been reported in the literature ( Table 3 ) (25, 26, 34, 42, 44, 45, 54) . Of these patients, 4 showed complement positivity at DAT evaluation (26, 34, 44, 45) . WAIHA flares occurred concomitantly with-or up to 21 days after initial COVID-19 detection and were mostly managed with transfusions and steroids. Only 2 patients required rituximab and 1 received cyclophosphamide. Notably, we previously reported 2 patients out of a cohort of 139 wAIHA patients who experienced a severe COVID-19 infection (42) . Only one experienced wAIHA reactivation 3 weeks after COVID-19 pneumonia and was effectively managed with steroids and intravenous immunoglobulins. Additionally, 5 cases of wAIHA (only 1 had DAT positive for IgG and C3d) developing or reactivating after mRNA SARS-CoV-2 vaccination have been described, 3 after the 1 st and 2 after the 2 nd dose ( Table 4 ) (23, 52, 54) . Three cases had a severe presentation (i.e., Hb<8 g/dL), 2 required transfusions and only one subject received therapy other than steroids (rituximab and mycophenolate). Overall, as outlined for patients with CAD, hemolytic flares after COVID-19 infection appear more severe than those occurring after vaccination and the same monitoring of blood counts and LDH should be applied.

The review of the literature showed a total of 9 patients with HUS associated with COVID-19 infection ( 

There is an association between COVID-19 and exacerbations of complement mediated hemolytic anemias. Although hemolytic flares in these diseases may be observed upon several infectious triggers (i.e., Mycoplasma pneumoniae, hepatitis, herpetic viruses, human immunodeficiency virus, Influenza virus, etc) (4, 60), and sporadically after other vaccines (i.e., Influenza vaccine) (61-63), SARS-CoV-2 seems to induce a higher and broader complement activation. Complement is clearly involved in the pathogenesis of COVID-19, namely respiratory failure, intravascular coagulopathy, and over-inflammation. Recently, it has been shown that a prominent activation of the alternative and lectin complement pathways identify a subset of severe COVID-19 patients with a higher proportion of fatalities, need of oxygen support, and ICU admission (64) (65) (66) (67) . If during COVID-19 infection alternative and lectin pathways are more involved, SARS-CoV-2 vaccine seems to mainly act through the classical pathway activation (21) . As a matter of fact, complement activation has a dichotomous nature since it does contribute to the hyper-inflammatory state but may also exert a neutralizing effect against SARS-CoV-2 infection. This may account for the controversial results of ongoing trials with complement inhibitors (18, 19, (68) (69) (70) . Likewise, immunosuppressive treatment in immune-mediated anemias may have a dual effect in reducing hyperinflammation and dampening immunocompetence. Patient education is pivotal to promptly recognize signs/ symptoms of hemolytic flares and to seek medical attention. The latter should be always high and should focus on the assessment of the severity of hemolytic exacerbation to prompt treatment choice (transfusions, complement inhibitor initiation/additional dose in the case of PNH, steroids/rituximab in the case of CAD and wAIHA, plasma exchange, hemodialysis and complement inhibitor in the case of aHUS) and anti-thrombotic prophylaxis. Since most episodes occurred within the first 10 days after COVID-19 infection/ vaccination, laboratory monitoring in that period appears feasible and cost-effective. Finally, hemolytic exacerbations occurring during COVID-19 infection were more severe, required higher therapeutic burden, and carried more complications including fatalities, as compared to those developing after SARS-CoV-2 vaccine. This highlights the importance of vaccinating this patient population but with meticulous monitoring for complications.

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

The studies involving human participants were reviewed and approved by Comitato Etico Milano Area 2. The patients/ participants provided their written informed consent to participate in this study. 

Increased Complement Activation Is a Distinctive Feature of Severe SARS-CoV-2 Infection

Highly Pathogenic Coronavirus N Protein Aggravates Lung Injury by MASP-2-Mediated Complement Over-Activation. medRxiv

Complement Inhibition and COVID-19: The Story So Far

How I Treat Paroxysmal Nocturnal Hemoglobinuria

New Insights in the Pathogenesis and Therapy of Cold Agglutinin-Mediated Autoimmune Hemolytic Anemia

Sutimlimab in Cold Agglutinin Disease

New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy

Hemolytic Crisis in a Patient Treated With Eculizumab for Paroxysmal Nocturnal Hemoglobinuria Possibly Triggered by SARS-CoV-2 (COVID-19): A Case Report

COVID19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria: A Case Report

Severe COVID-19 Infection in a Patient With Paroxysmal Nocturnal Hemoglobinuria on Eculizumab Therapy

Severe Hemolysis in a COVID-19 Patient With Paroxysmal Nocturnal Hemoglobinuria

Terminal Complement Inhibition Dampens the Inflammation During COVID-19

Griffin M COVID-19 Infection in Patients on Anti-Complement Therapy: The Leeds National Paroxysmal Nocturnal Hemoglobinuria Service Experience

Reddy R Mild Clinical Course of COVID-19 in 3 Patients Receiving Therapeutic Monoclonal Antibodies Targeting C5 Complement for Hematologic Disorders

Covid-19 Infection in Patients With PNH: An Italian Multicenter Survey

Complement as a Target in COVID-19?

Repurposed Immunomodulatory Drugs for Covid-19 in Pre-ICu Patients -mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 -Repurposed Drugs (TACTIC-R): A Structured Summary of a Study Protocol for a Randomised Controlled Trial

Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia

Brodsky RA Direct Activation of the Alternative Complement Pathway by SARS-CoV-2 Spike Proteins Is Blocked by Factor D Inhibition

COVID-19 Vaccines Induce Severe Hemolysis in Paroxysmal Nocturnal Hemoglobinuria

Autoimmune-and Complement-Mediated Hematologic Condition Recrudescence Following Sars-Cov-2 Vaccination

Sars-CoV2-Vaccination Induces Breakthrough Hemolysis in PNH on Complement Inhibitor

Thrombotic Events With Neisseria Meningitidis Vaccination in Patients With Paroxysmal Nocturnal Hemoglobinuria, UK Experience

A 3-Case Series of Autoimmune Haemolytic Anaemia and COVID-19: Is Plasma Exchange an Alternative?

Autoimmune Haemolytic Anaemia Associated With COVID-19 Infection

Cold Agglutinin Associated With COVID-19 Infection in a Thalassemia Patient With Multiple Alloantibodies: A Case of Cold Hemagglutinin Disease (CAD) With Complex Antibody Detection

Cold Agglutinin Autoimmune Haemolytic Anaemia Associated With Novel Coronavirus (COVID-19)

Cold Agglutinin Disease and Autoimmune Hemolytic Anemia With Pulmonary Embolism as a Presentation of COVID-19 Infection

Cold Agglutinin Disease and COVID-19 Requiring Therapeutic Plasma Exchange

Cold Agglutinin Disease Following SARS-CoV-2 and Mycoplasma Pneumoniae Co-Infections

Coronavirus Disease 2019 and Cold Agglutinin Syndrome: An Interesting Case

COVID-19 and Cold Agglutinin Hemolytic Anemia

COVID-19 Associated With Severe Autoimmune Hemolytic Anemia

COVID-19 Infection Associated With Autoimmune Hemolytic Anemia

SARS-CoV-2 Infection Complicated With Cold Agglutinin Disease and Myositis

SARS-CoV-2-Associated Cold Agglutinin Disease: A Report of Two Cases

Serological Blood Group Discrepancy and Cold Agglutinin Autoimmune Hemolytic Anemia Associated With Novel Coronavirus Cureus

Transient Cold Agglutinins in a Patient With COVID-19

COVID-19 Presenting With Autoimmune Hemolytic Anemia in the Setting of Underlying Immune Dysregulation

High Thermal Amplitude Red Blood Cell Agglutinating Cold Type Autoantibodies in a Case of Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia and Multiorgan Failure

Are Patients With Autoimmune Cytopenias at Higher Risk of COVID-19 Pneumonia? The Experience of a Reference Center in Northern Italy and Review of the Literature

A Case of COVID-19-Associated Autoimmune Hemolytic Anemia With Hyperferritinemia in an Immunocompetent Host

Warm Autoimmune Hemolytic Anemia Associated With Asymptomatic SARS-CoV-2

Prognostic Significance of Hemoglobin Level and Autoimmune Hemolytic Anemia in SARS-CoV-2 Infection

Molecular Mimicry may Explain Multi-Organ Damage in COVID-19

COVID-19: Fighting the Invisible Enemy With microRNAs

Physical Phenotype of Blood Cells Is Altered in COVID-19

Evans Syndrome and Infections: A Dangerous Cocktail to Manage With Caution

Cold Agglutinin Disease After COVID-19 Vaccine

A Case of Autoimmune Hemolytic Anemia Following COVID-19 Messenger Ribonucleic Acid Vaccination

SARS-CoV-2 Vaccination in Patients With Autoimmune Cytopenias: The Experience of a Reference Center

Severe Autoimmune Hemolytic Anemia Following Receipt of SARS-CoV-2 mRNA Vaccine

Hemolytic Crisis Due to Covid-19 Vaccination in a Woman With Cold Agglutinin Disease

COVID-19 as a Potential Trigger of Complement-Mediated Atypical HUS

Atypical HUS Triggered by Infection With SARS-Cov2

Atypical HUS Relapse Triggered by COVID-19

Alternating Hemiparesis in the Context of Hemolytic Uremic Syndrome and COVID-19 Positivity

Autoimmune Hemolytic Anemia in Adults: Primary Risk Factors and Diagnostic Procedures

Autoimmune Hemolytic Anemia Following MF59-Adjuvanted Influenza Vaccine Administration: A Report of Two Cases

Autoimmune Hemolytic Anemia in a Renal Transplant Patient Following Seasonal Influenza Vaccination

Paroxysmal Nocturnal Hemoglobinuria Diagnosed After Influenza Vaccine: Coincidence or Consequence?

Complement Alternative and Mannose-Binding Lectin Pathway Activation Is Associated With COVID-19 Mortality

The Outcome of Critically Ill COVID-19 Patients Is Linked to Thromboinflammation Dominated by the Kallikrein/Kinin System

Complement Activation in Patients With Covid-19: A Novel Therapeutic Target

Mannose-Binding Lectin Is Associated With Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients

Covid-19 Infected Patients (SOLID-C19). Available at

Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)

All authors equally contributed to the present article.

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.